GT200600250A - Moduladores de quinasas con estructuras de alquilquinolina y alquilquinazolina referencia cruzada con solicitudes relacionadas - Google Patents

Moduladores de quinasas con estructuras de alquilquinolina y alquilquinazolina referencia cruzada con solicitudes relacionadas

Info

Publication number
GT200600250A
GT200600250A GT200600250A GT200600250A GT200600250A GT 200600250 A GT200600250 A GT 200600250A GT 200600250 A GT200600250 A GT 200600250A GT 200600250 A GT200600250 A GT 200600250A GT 200600250 A GT200600250 A GT 200600250A
Authority
GT
Guatemala
Prior art keywords
alquilquinolina
alquilquinazolina
compounds
related applications
kinase modulators
Prior art date
Application number
GT200600250A
Other languages
English (en)
Inventor
Nand Baindur
Michael David Gaul
Kevin Douglas Kreutter
Guozhang Xu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600250A publication Critical patent/GT200600250A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

LA INVENCIÓN SE REFIERE A COMPUESTOS CON ESTRUCTURA DE ALQUILQUINOLINA Y ALQUILQUINAZOLINA DE FÓRMULA (I), DONDE R1, R2, R3, B, Z, G, Q Y X SON COMO SE LOS DEFINIÓ EN EL EXPEDIENTE, AL USO DE TALES COMPUESTOS COMO MODULADORES DE PROTEÍNAS TIROSINA QUINASAS, EN PARTICULAR INHIBIDORES DE FLT3 Y/O C-KIT Y/O TRKB EN UNA CÉLULA O UN SUJETO, Y AL USO DE TALES COMPUESTOS PARA PREVENIR O TRATAR EN UN SUJETO UN TRASTORNO DE PROLIFERACIÓN CELULAR Y/O TRASTORNOS RELACIONADOS CON FLT3 Y/O C-KIT Y/O TRKB. LA PRESENTE INVENCIÓN SE REFIERE ADEMÁS A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS DE LA PRESENTE INVENCIÓN Y A MÉTODOS PARA TRATAR AFECCIONES TALES COMO CÁNCERES Y OTROS TRASTORNOS PROLIFERATIVOS CELULARES. T2006
GT200600250A 2005-06-10 2006-06-08 Moduladores de quinasas con estructuras de alquilquinolina y alquilquinazolina referencia cruzada con solicitudes relacionadas GT200600250A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68938405P 2005-06-10 2005-06-10
US73091905P 2005-10-27 2005-10-27
US78955106P 2006-04-05 2006-04-05

Publications (1)

Publication Number Publication Date
GT200600250A true GT200600250A (es) 2007-03-14

Family

ID=37038264

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600250A GT200600250A (es) 2005-06-10 2006-06-08 Moduladores de quinasas con estructuras de alquilquinolina y alquilquinazolina referencia cruzada con solicitudes relacionadas

Country Status (20)

Country Link
US (1) US7825244B2 (es)
EP (1) EP1891040A1 (es)
JP (1) JP2008545787A (es)
KR (1) KR20080033234A (es)
AR (1) AR054387A1 (es)
AU (1) AU2006258056A1 (es)
BR (1) BRPI0612543A2 (es)
CA (1) CA2611219A1 (es)
CR (1) CR9651A (es)
EA (1) EA200800010A1 (es)
EC (1) ECSP077993A (es)
GT (1) GT200600250A (es)
IL (1) IL187688A0 (es)
MX (1) MX2007015739A (es)
NI (1) NI200700312A (es)
NO (1) NO20080160L (es)
PA (1) PA8679201A1 (es)
TW (1) TW200718694A (es)
UY (1) UY29589A1 (es)
WO (1) WO2006135646A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8880138B2 (en) * 2005-09-30 2014-11-04 Abbott Diabetes Care Inc. Device for channeling fluid and methods of use
KR101744033B1 (ko) * 2013-10-16 2017-06-07 후지필름 가부시키가이샤 함질소 복소환 화합물의 염 또는 그 결정, 의약 조성물 및 flt3 저해제
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517005A (en) * 1967-10-26 1970-06-23 Pfizer & Co C Certain 2- and 4-substituted quinazolines
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
JPS5976082A (ja) 1982-10-23 1984-04-28 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
GB8320958D0 (en) * 1983-08-03 1983-09-07 Pfizer Ltd Quinazoline cardiac stimulants
US5300515A (en) * 1991-01-31 1994-04-05 Kyorin Pharmaceutical Co., Ltd. Carbamic acid derivatives and method for preparing the same
ATE239506T1 (de) * 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
CA2216943C (en) 1995-04-19 2003-06-17 Schneider (Usa) Inc. Drug release coated stent
WO1997028118A1 (en) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Process for preparing anthranilic acids
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
AU2521597A (en) 1996-04-12 1997-11-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyramidine derivatives
CA2239227C (en) 1996-10-01 2007-10-30 Kenji Matsuno Nitrogen-containing heterocyclic compounds
US5866562A (en) * 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
CA2313125A1 (en) 1997-12-12 1999-06-24 Laramie Mary Gaster Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
DE19756388A1 (de) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
EP1230225A2 (en) 1999-11-01 2002-08-14 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
EP1309567A2 (en) 2000-08-18 2003-05-14 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds
EP1309569B1 (en) 2000-08-18 2010-10-06 Millennium Pharmaceuticals, Inc. N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors
AU2687702A (en) 2000-10-17 2002-04-29 Merck & Co Inc Orally active salts with tyrosine kinase activity
DE60115092T2 (de) 2000-12-12 2006-03-30 Neurogen Corp., Brandford Spiro[isobenzofuran-1,4'-piperidin]-3-one und 3h-spiroisobenzofuran-1,4'-piperidine
DE10109866A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE60227794D1 (de) 2001-04-26 2008-09-04 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
PT1441737E (pt) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
CN1290844C (zh) 2001-12-27 2006-12-20 施万制药 用作蛋白激酶抑制剂的二氢吲哚酮衍生物
CA2473572C (en) 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
WO2004002960A1 (en) 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
PL375447A1 (en) 2002-08-14 2005-11-28 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
AU2003280599A1 (en) 2002-10-29 2004-05-25 Kirin Beer Kabushiki Kaisha QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
EP1565187A4 (en) 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic CANCER TREATMENT METHODS AND RELATED METHODS
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
EP1581526B1 (en) 2002-12-18 2009-03-11 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
DE602004022318D1 (de) 2003-10-14 2009-09-10 Supergen Inc Proteinkinaseinhibitoren
RU2006121990A (ru) 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) * 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators

Also Published As

Publication number Publication date
AU2006258056A1 (en) 2006-12-21
IL187688A0 (en) 2008-08-07
UY29589A1 (es) 2006-10-02
EP1891040A1 (en) 2008-02-27
NI200700312A (es) 2009-02-19
ECSP077993A (es) 2008-01-23
BRPI0612543A2 (pt) 2010-11-23
EA200800010A1 (ru) 2008-06-30
KR20080033234A (ko) 2008-04-16
JP2008545787A (ja) 2008-12-18
CA2611219A1 (en) 2006-12-21
US20070021436A1 (en) 2007-01-25
NO20080160L (no) 2008-01-09
PA8679201A1 (es) 2007-01-17
CR9651A (es) 2008-09-09
TW200718694A (en) 2007-05-16
AR054387A1 (es) 2007-06-20
WO2006135646A1 (en) 2006-12-21
MX2007015739A (es) 2008-04-29
US7825244B2 (en) 2010-11-02

Similar Documents

Publication Publication Date Title
GT200600248A (es) Aminopirimidinas como moduladores de quinasas
GT200600253A (es) Aminopirimidinas como moduladores de quinasas
UY29588A1 (es) Moduladores de quinasas con estructuras de alquilquinolina y alquilquinazolina
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
SV2008002963A (es) Triazolopiridazinas como moduladores de tirosina cinasa referencia cruzada con solicitudes relacionadas ref. prd2584sv
ECSP077998A (es) Moduladores de cinasa de aminoquinolina y aminoquinazolina
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
ECSP088598A (es) Derivados de piridazinona
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
GT200500272A (es) 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos
CL2008003873A1 (es) Compuestos derivados de benzofuropirimidinona sustituidos, inhibidores de proteinas quinasas; composicion farmaceutica que comprende a uno de los compuestos; metodo para inhibir in vitro proteinas quinasa (pim, cdc7,ck2); y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer
NI200700311A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de la cinasa de flt-3
UY29732A1 (es) Derivados de benzotiazolonas, procesos de preparación, composiciones y combinaciones que los contienen y aplicaciones
UY33130A (es) Derivados de imidazopiridina como inhibidores de jak
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
ECSP10010361A (es) Derivados de piridazinona
ECSP11010904A (es) Compuestos de pirrolo[2,3-d]pirimidina
SV2010003776A (es) Derivados de pirimidina como inhibidores de cinasa
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2011000489A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala
UY29440A1 (es) Nuevos compuestos
ECSP10010129A (es) Inhibidores de quinasas símil polo
UY32529A (es) Compuestos heterocíclicos y su uso como inhibidores de la glucógeno sintetasa quinasa 3
ECSP11011172A (es) Derivados de tieno [3,2-c]piridina como inhibidores de quinasas para el uso en el tratamiento del cáncer.
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización